Monument Biosciences is a preclinical stage biopharmaceutical company bringing forward the next generation of disease modifying drugs for Alzheimer’s Disease and Related Dementias (ADRD). Our discovery programs are anchored in human patient genetics, recent discoveries around tau homeostasis and tau seeding, and the role of microglia in neuroinflammation. Our approach relies on translational biomarkers to treat the right patients and follow their disease progress in response to therapy – informing clinical strategy, safety, and patient benefit. Based in Indianapolis, Indiana, the team is comprised of leading neuro focused scientists, clinicians, and entrepreneurs from Eli Lilly, Stark Neurosciences Research Institute, and Luson Bioventures with a proven track record in venture creation & drug development.
